Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


‘Breakthrough’ Drugs Get ‘Road-MaPP’ – Complete With Communication Timetable

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER Manual of Policy and Procedures describes specific actions FDA review staff will take once a product has received “breakthrough therapy” designation, with an emphasis on more meetings, more frequently.

You may also be interested in...

Surge In Applications Triggers User Fee Inflation

With full NDA and BLA submissions to FDA now growing faster than INDs and supplements, user fees are increasing more rapidly as well.

Breakthrough Designation Is A Two-Way Street, FDA Cautions Sponsors

Sponsors of would-be breakthrough therapies need to move as quickly as FDA is acting, from responding to emails to ramping up manufacturing so they can start trials earlier.

REMS, ‘Breakthrough’ Meetings Get ‘Type B’ Tag In Revised FDA Guidance

In other modifications, FDA tells sponsors seeking Type A meetings – the most urgent category – that data packages must accompany the request.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts